Trial · NCT00274924

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00274924, Phase 2, Completed, Eastern Cooperative Oncology Group; results first posted 2014-02-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma. Trials, record NCT00274924. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00274924

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT number: NCT00274924
Status: Completed
Phases: Phase 2
Enrollment: 100 participants, actual
Lead sponsor: Eastern Cooperative Oncology Group
Conditions: Lymphoma
Interventions: filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
First posted: 2006-01-11
Last updated: 2023-06-29
Results first posted: 2014-02-24

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	2-year Progression-Free Survival (PFS)	Assessed every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.	2-year progression-free survival is defined as the probability of patients who remain alive and progression free at 2 years from study entry. The method of Kaplan and Meier (1958) was used to estimate PFS.
Secondary	5-year Overall Survival	Every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.	5-year overall survival is defined as the probability of patients who remain alive at 5 years from study entry. The method of Kaplan and Meier (1958) was used to estimate overall survival.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	2-year Progression-Free Survival (PFS)	Assessed every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.		probability	NUMBER
SECONDARY	5-year Overall Survival	Every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.		probability	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
2-year Progression-Free Survival (PFS)	Group I (PET Negative)	0.76	90% Confidence Interval 0.65 to 0.84	probability
2-year Progression-Free Survival (PFS)	Group II (PET Positive)	0.42	90% Confidence Interval 0.19 to 0.63	probability
5-year Overall Survival	Group I (PET Negative)	0.77	90% Confidence Interval 0.49 to 0.91	probability
5-year Overall Survival	Group II (PET Positive)	0.69	90% Confidence Interval 0.43 to 0.85	probability

Source ClinicalTrials.gov

Participant flow27

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Step 1 (R-CHOP X 3 Cycles)	STARTED	Group I (PET Positive)	17
Step 1 (R-CHOP X 3 Cycles)	STARTED	Group II (PET Negative)	77
Step 1 (R-CHOP X 3 Cycles)	STARTED	No Mid-Treatment PET	6
Step 1 (R-CHOP X 3 Cycles)	Treated	Group I (PET Positive)	17
Step 1 (R-CHOP X 3 Cycles)	Treated	Group II (PET Negative)	77
Step 1 (R-CHOP X 3 Cycles)	Treated	No Mid-Treatment PET	5
Step 1 (R-CHOP X 3 Cycles)	Eligible and Treated	Group I (PET Positive)	13
Step 1 (R-CHOP X 3 Cycles)	Eligible and Treated	Group II (PET Negative)	63
Step 1 (R-CHOP X 3 Cycles)	Eligible and Treated	No Mid-Treatment PET	4
Step 1 (R-CHOP X 3 Cycles)	COMPLETED	Group I (PET Positive)	13

1 to 10 of 27Source ClinicalTrials.gov

See all 27 participant flow

Adverse events351

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Step 1 - All Treated Patients	0	99
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Step 2 - Mid-treatment PET Positive	1	17
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Step 2 - Mid-treatment PET Negative	1	76
other	Anemia	Blood and lymphatic system disorders	Step 1 - All Treated Patients	73	99
other	Anemia	Blood and lymphatic system disorders	Step 2 - Mid-treatment PET Positive	16	17
other	Anemia	Blood and lymphatic system disorders	Step 2 - Mid-treatment PET Negative	57	76
other	Leukocytes decreased	Investigations	Step 1 - All Treated Patients	39	99
other	Leukocytes decreased	Investigations	Step 2 - Mid-treatment PET Positive	8	17
other	Leukocytes decreased	Investigations	Step 2 - Mid-treatment PET Negative	25	76
other	Lymphopenia	Investigations	Step 1 - All Treated Patients	11	99

1 to 10 of 351Source ClinicalTrials.gov

See all 351 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Step 1 - All Treated Patients
Total, all-cause mortality	Step 2 - Mid-treatment PET Positive
Total, all-cause mortality	Step 2 - Mid-treatment PET Negative
Total, other adverse events	Step 1 - All Treated Patients	97	99
Total, other adverse events	Step 2 - Mid-treatment PET Positive	17	17
Total, other adverse events	Step 2 - Mid-treatment PET Negative	75	76
Total, serious adverse events	Step 1 - All Treated Patients	58	99
Total, serious adverse events	Step 2 - Mid-treatment PET Positive	17	17
Total, serious adverse events	Step 2 - Mid-treatment PET Negative	25	76

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19767508	RESULT

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA021115	Eastern Cooperative Oncology Group Operations Office	COMIS, ROBERT L	FRONTIER SCI & TECHNOLOGY RSCH FDN, INC	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00274924

GET https://conductscience.org/api/trials/v1/NCT00274924/flow?page=2

API reference For AI assistants